Summary : For a resident patentee whose AY 2026-27 return falls in the audit category covered by CBDT Circular No. 07/2026, 21 November 2026 is the operative return due date. Section 115BBF(3) of the Income-tax Act, 1961 ties the patent-royalty option to the due date under section 139(1); Form 3CFA should therefore be completed by that revised date for the covered category. The option is narrow. It applies to royalty from a patent developed and registered in India, the claimant must be resident in India and entered as the true and first inventor on the patent register, and at least 75% of the invention-development expenditure must have been incurred in India. Qualifying royalty is taxed at 10% under section 115BBF, but no expenditure or allowance is deductible against that royalty. Consideration for sale of a patented product, capital-gains consideration and other receipts outside the statutory royalty definition do not enter the special base merely because a patent is commercially relevant. The decision also has continuity consequences: if the option is used and the income is not offered under the regime in any of the next five assessment years, the benefit is denied for five subsequent assessment years. This guide separates the filing deadline, eligibility evidence, royalty computation and governance needed before the option is submitted.
- Why 21 November 2026 Is the Relevant Date for the Covered Category
- Section 115BBF Eligibility Starts With the Patentee, Not the Payer
- Resident and patent-register conditions
- The invention must be developed and registered in India
- Only Statutory Patent Royalty Enters the 10% Computation
- Form 3CFA Must Reconcile to the Return and the Patent File
- The Five-Year Continuity Rule Changes the Decision
- Eight-Day Filing Control for 13–21 November
- Frequently Asked Questions
- Is Form 3CFA due on 21 November 2026 for every patentee?
- Does a company that owns an assigned patent automatically qualify?
- What does “developed in India” mean for this section?
- Is royalty taxed at 10% after deducting research expenditure?
- Are sales of patented products treated as royalty?
- Which form applies to AY 2026-27: Form 3CFA or Form 65?
- Can the assessee leave the regime next year without consequence?
- Key Takeaways
Why 21 November 2026 Is the Relevant Date for the Covered Category
CBDT Circular No. 07/2026 dated 28 September 2026 extended the AY 2026-27 return due date from 31 October 2026 to 21 November 2026 for the persons at serial number 2 of the table below Explanation 2 to section 139(1). That category includes a company and a non-company person whose accounts must be audited under the Income-tax Act or another law, where section 92E does not apply, together with the specified partner and spouse cases. The circular did not extend the 30 November date applicable to section 92E cases.
Section 115BBF(3) requires the eligible assessee to exercise the option in the prescribed manner on or before the due date specified under section 139(1) for the relevant year. Rule 5G prescribes Form 3CFA. Because the form deadline is linked to the return due date rather than stated as a separate fixed calendar date, the revised 21 November date governs a claimant whose return is within the circular’s covered category. A claimant with a 30 November return date should apply its own statutory due date; the circular should not be extended by analogy to a person outside it.
| AY 2026-27 claimant profile | Return date | Form 3CFA control |
|---|---|---|
| Audit-category person covered by Circular 07/2026; no section 92E report | 21 November 2026 | File the option by the revised section 139(1) due date |
| Person required to furnish a section 92E report | 30 November 2026 | Circular 07/2026 does not alter this category |
| Person whose original due date was not 31 October 2026 | Date applicable to that person | Do not borrow the circular’s relief without statutory coverage |
Section 115BBF Eligibility Starts With the Patentee, Not the Payer
Resident and patent-register conditions
An eligible assessee is a person resident in India who is a patentee. For this purpose, patentee means the true and first inventor whose name is entered on the patent register and includes each such inventor where more than one true and first inventor is registered. An assignee or company that commercially owns rights should not assume eligibility merely from a licence, assignment or revenue stream. The current patent register, inventor identity and tax residence should be matched before the form is prepared.
The invention must be developed and registered in India
The patent must be registered in India. In addition, “developed” means that at least 75% of the expenditure incurred for the invention in respect of which the patent is granted was incurred in India by the eligible assessee. This is an expenditure-location test, not a broad assertion that research took place in India. The working paper should identify the invention, map expenditure to it, distinguish Indian and overseas spend, explain allocations and preserve invoices, payroll records, research agreements and project ledgers.
Only Statutory Patent Royalty Enters the 10% Computation
Section 115BBF defines royalty for the patent regime as consideration, including a non-returnable advance, for transfer or licensing of patent rights, information concerning the working or use of a patent, use of a patent, or services connected with those activities. The definition excludes consideration that is chargeable as capital gains and consideration for sale of a product manufactured using the patented process or for commercial use of the patented article. Contract labels are therefore not decisive: a bundled payment may need a supportable allocation between qualifying royalty and non-qualifying goods, services or rights.
The tax on qualifying royalty is calculated at 10%, while the balance of total income is taxed as if the royalty amount were removed. Surcharge and health and education cess must be considered under the applicable law. No deduction for expenditure or allowance is available in computing the royalty income placed in the special-rate basket. The comparison should therefore use qualifying gross royalty, not an accounting profit after research, legal, employee, amortisation or marketing costs.
| Receipt or fact pattern | Section 115BBF treatment issue | Evidence |
|---|---|---|
| Licence fee for use of an Indian patent | Potential royalty if all eligibility conditions are met | Executed licence, patent number and invoice trail |
| Non-returnable advance against licence royalty | Expressly included in royalty definition | Advance clause and revenue recognition support |
| Sale of products made using patented process | Excluded from patent royalty definition | Sales contracts and product invoices |
| Transfer consideration chargeable as capital gains | Excluded from the special royalty definition | Transfer agreement and capital-gain computation |
| Bundled technology and support fee | Allocate only on defensible contractual and valuation basis | Scope, pricing schedule and allocation memo |
Form 3CFA Must Reconcile to the Return and the Patent File
Rule 5G requires the option through Form 3CFA in the prescribed electronic manner. The filing file should reconcile the assessee’s legal identity and PAN to the patent register, identify the relevant patents, state the royalty income, and connect the form amounts to the return schedules and books. If several patents or licences are involved, a patent-by-patent bridge reduces the risk that an ineligible receipt is swept into the 10% line.
The option should not be filed as a last-day portal exercise. The responsible team should confirm that the AY 2026-27 return is governed by the 1961 Act and the related 1962 Rules and forms, even though the Income-tax Act, 2025 applies from 1 April 2026 for Tax Year 2026-27 onward. The department’s official transition material identifies Form 3CFA as the 1962 Rules form and Form 65 as its 2026 Rules successor. Mixing Form 65 into an AY 2026-27 filing would be a period error.
The Five-Year Continuity Rule Changes the Decision
After an assessee opts into section 115BBF for a previous year, the statute tests the next five assessment years. If patent royalty is offered in any of those years otherwise than under the special regime, the assessee becomes ineligible for section 115BBF for five assessment years following the assessment year of the departure. The decision should therefore consider expected licensing income, deductions that will be forgone, ownership changes, patent transfers and administrative capability across a multi-year horizon.
A governance memo should record why the option is beneficial and legally available, who approved it, and how future-year compliance will be tracked. This is not a recommendation to choose the special rate. A 10% headline rate may be unattractive where significant expenditure would otherwise be deductible, and the answer depends on the claimant’s facts, surcharge, cess and other provisions.
Eight-Day Filing Control for 13–21 November
- Confirm the claimant’s section 139(1) category and document why Circular 07/2026 applies.
- Match each patent to the official register and the true-and-first-inventor condition.
- Compute and evidence the 75% India-development expenditure test for each invention.
- Separate statutory royalty from product sales, capital-gain consideration and other receipts.
- Model the 10% gross-royalty tax against ordinary treatment, including surcharge and cess.
- Reconcile Form 3CFA to the books and AY 2026-27 return, then retain acknowledgement.
- Create a five-assessment-year continuity tracker if the option is exercised.
Frequently Asked Questions
Is Form 3CFA due on 21 November 2026 for every patentee?
No. That date follows for a claimant whose AY 2026-27 return is in the audit category covered by Circular 07/2026. Other claimants must use their own section 139(1) due date.
Does a company that owns an assigned patent automatically qualify?
No. The statutory eligible-patentee definition focuses on a resident true and first inventor entered on the patent register. Ownership documents and the register must be reviewed.
What does “developed in India” mean for this section?
At least 75% of the expenditure incurred by the eligible assessee for the relevant invention must have been incurred in India.
Is royalty taxed at 10% after deducting research expenditure?
No. Section 115BBF does not allow deduction of expenditure or allowance in computing the qualifying royalty income placed under the special rate.
Are sales of patented products treated as royalty?
No. Consideration for sale of a product manufactured with a patented process or for commercial use of a patented article is excluded from the statutory royalty definition.
Which form applies to AY 2026-27: Form 3CFA or Form 65?
Form 3CFA under the Income-tax Rules, 1962 applies to AY 2026-27. Form 65 is the corresponding form under the Income-tax Rules, 2026 for the new-law period.
Can the assessee leave the regime next year without consequence?
A departure during the next five assessment years triggers a statutory five-assessment-year period of ineligibility following the year of departure.
Key Takeaways
- For the covered audit-return category, 21 November 2026 is the linked Form 3CFA deadline.
- Eligibility depends on resident true-inventor status, Indian registration and the 75% India-expenditure test.
- The 10% rate applies to qualifying gross royalty; deductions are not allowed against that amount.
- Product-sale and capital-gain consideration are outside the special royalty definition.
- The option requires a five-year continuity plan and an AY 2026-27 Form 3CFA, not new-law Form 65.
*****
Disclaimer: This article is a general educational analysis of section 115BBF of the Income-tax Act, 1961, rule 5G and Form 3CFA of the Income-tax Rules, 1962, and CBDT Circular No. 07/2026, checked on 13 November 2026. It does not determine whether any person is an eligible patentee, whether a patent was developed or registered in India, whether the 75% expenditure test is met, whether a receipt is royalty, capital gains, product-sale consideration or another category, or whether exercising the option produces a lower final tax. The 21 November 2026 date discussed here applies only where the claimant’s AY 2026-27 return belongs to the category expressly covered by the circular; persons covered by section 92E and other return categories must determine their own due date. Patent ownership, inventor status, residence, expenditure location, bundled contracts, foreign receipts, withholding, transfer pricing, surcharge, cess, minimum-tax provisions, treaty issues and return schedules require fact-specific review. The option disallows deductions against qualifying royalty and creates multi-year consequences, so a headline 10% rate is not a sufficient decision rule. Portal availability, validation rules and official guidance can change, and the filing acknowledgement and return reconciliation must be retained. Taxpayers should verify the live statute, rules, circular, form and portal immediately before filing and obtain advice from qualified tax, patent and legal professionals. TaxGuru accepts no responsibility or liability for any missed deadline, rejected form, denied rate, additional tax, interest, penalty, loss of deduction, patent dispute, continuity consequence or commercial loss arising from reliance on this article, incomplete records, incorrect classification or subsequent legal, factual or system changes.
